CRL

Business Profile & Competitive Position

Charles River Laboratories International, Inc. operates in the Healthcare sector under the Medical – Diagnostics & Research industry. Its core business is serving as a full-service, non-clinical global drug-development partner, providing research model technologies, discovery and safety assessment services, and manufacturing support products. The company reports through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.

On a reported revenue base of $4.0 billion, the segment split was DSA at 59.8%, RMS at 21.1%, and Manufacturing at 19.1%. That concentration makes DSA the dominant economic engine, while RMS supplies the live research models and related services that feed into broader discovery workflows.

When moat quality is reasoned from the financials, the picture is mixed. Net margin is negative at -6.0% and ROE is negative at -7.7%. Those figures do not support a strong, durable economic moat in the classic sense of excess returns on capital or pricing power. A diagnostics and research services business with negative profitability is likely operating in a competitive, price-sensitive environment or absorbing restructuring and acquisition-related costs. Offsetting that, the company runs more than 120 sites across more than 20 countries, which implies scale, long-term client relationships, and integration into pharmaceutical and biotech R&D supply chains. Still, at the margin level, the numbers indicate the competitive position has been under pressure rather than widening.

Financial Posture

Charles River currently carries a market capitalization of $14.2 billion. Its P/E ratio is -61.0, reflecting that the trailing-twelve-month earnings figure is negative. The negative net margin of -6.0% and negative ROE of -7.7% confirm the company is not currently generating accounting profits.

Volatility and valuation technicals also stand out. The stock’s beta is 1.38, meaning it has historically moved roughly 38% more than the broad market and is more sensitive to swings in risk appetite. The current price is $295.19, the 50-day exponential moving average is $240.08, and the RSI is 76.3. An RSI above 70 is generally read as a technically overbought condition, while the gap between the current price and the 50-day EMA shows the stock has extended well above its near-term average.

Taken together, the financial posture is one of a large, global healthcare services company with meaningful scale but weak current earnings conversion and elevated recent price momentum.

Strategic Priorities & Outlook

The company’s most recent 10-K filing outlines a near-term operational agenda focused on footprint optimization, organizational integration, and portfolio expansion.

First, Charles River intends to optimize its global footprint by closing or consolidating approximately 12 additional sites over the next two years, principally within the DSA and RMS segments. That suggests management is trying to reduce fixed costs and streamline the asset base while it works back toward profitability.

Second, the company is integrating Discovery Services and Safety Assessment into one overarching DSA organization with a combined sales force and leadership structure. The goal is to present a unified DSA offering rather than operating discovery and safety as separate go-to-market units.

Third, the strategic objective remains to be the scientific partner of choice by delivering a comprehensive and integrated portfolio to accelerate biomedical research and therapeutic innovation.

Fourth, the company plans to continue expanding Biologics Testing Solutions service offerings and facilities in the U.S. and Europe, which aligns with the manufacturing segment’s 19.1% revenue share and the broader growth of biologics development.

Finally, in January 2026 the company acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. That deal directly tightens the supply chain for research models used in safety assessment work.

Macro & Geopolitical Exposure

As a Healthcare/Medical – Diagnostics & Research company, Charles River faces macro and geopolitical exposures typical of the contract research and laboratory services industry.

Regulatory risk is central. The company’s clients rely on non-clinical safety data to support FDA and other global drug-approval submissions. Any tightening of Good Laboratory Practice (GLP) standards, animal-welfare regulations, or environmental rules affecting research-model breeding facilities could raise compliance costs or restrict capacity.

Animal-welfare and sourcing regulations are particularly relevant given the use of non-human primates and other research models. Import restrictions, export bans, or reputational pressures on primate supply chains could affect both RMS revenue and DSA study execution.

Trade policy and cross-border logistics matter because the company operates across more than 20 countries. Tariffs, customs delays, or sanctions on biologic shipments can disrupt the movement of live models, tissue samples, and testing materials. Currency fluctuation is another factor: a strong U.S. dollar can compress the value of international revenue when translated back into dollars, while a weaker dollar can have the opposite effect.

On the demand side, the business is tied to pharmaceutical and biotechnology R&D budgets. Those budgets can be sensitive to credit conditions, venture-capital availability, and broader risk sentiment, which helps explain the stock’s 1.38 beta.

Recent Developments

Recent news flow has centered on institutional buying and strong price momentum.

On August 24, 2026, Great Lakes Advisors LLC disclosed a new $459,000 investment in Charles River Laboratories, according to defenseworld.net. New institutional positions are often interpreted as a vote of confidence, though the dollar size is modest relative to the $14.2 billion market cap.

On August 21, 2026, Zacks published two articles highlighting the stock’s recent performance. One noted that CRL had jumped 33.3% in the past month and asked whether the rally could keep running. The other reported that Charles River had gained 88.6% over the prior year and explored what was driving the rally. Those figures align with the current RSI of 76.3 and the large premium to the 50-day EMA, both of which point to a sharp, momentum-driven advance.

It is worth noting that these headlines describe price action rather than new fundamental developments, so they should be read alongside the company’s earnings record and strategic plan rather than as standalone catalysts.

Earnings Behavior & Post-Earnings Drift

Charles River’s earnings track record over the past eight quarters is perfect from a beat-rate perspective: it has beaten consensus in all eight reported quarters, for a 100% beat rate. The average earnings surprise across those eight quarters is 9.3%, which indicates the company has consistently delivered results above the market’s real expectation.

The average 5-day price move in the five trading days after earnings is 1.24%, classified as an upward post-earnings drift. That suggests that, on average, positive earnings news continues to be digested gradually rather than fully priced in on the release day.

The most recent four quarters show more nuance. On August 5, 2026, the company reported EPS of $3.02 against an estimate of $2.74, a 10.2% surprise; the stock rose 1.84% the next day and 9.07% over the following five days. On May 7, 2026, EPS of $2.06 beat the $1.96 estimate by 5.1%, yet the stock fell 2.23% the next day and dropped 12.42% over the next five sessions. On February 18, 2026, EPS of $2.39 beat the $2.33 estimate by 2.6%, with the stock up 3.95% the next day and 6.05% over the next five days. On November 5, 2025, EPS of $2.43 beat the $2.32 estimate by 4.7%, producing a 1.9% next-day gain and a 2.27% five-day gain.

The unofficial consensus heading into the next report, scheduled for November 4, 2026 before the open, is EPS of $2.97. Traders typically watch whether the streak of beats can continue and whether the post-earnings price reaction follows the historical upward drift pattern or breaks from it.

For a deeper dive into how institutions are collectively weighing these fundamentals, momentum signals, and earnings setup, readers should review the full institutional verdict and aggregated analyst view for CRL.